BOSTON SCIENTIFIC v. NEVRO CORP. , No. 21-1777 (Fed. Cir. 2022)
Annotate this Case
Download PDF
Case: 21-1777 Document: 40 Page: 1 Filed: 03/18/2022 NOTE: This disposition is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ BOSTON SCIENTIFIC NEUROMODULATION CORP., Appellant v. NEVRO CORP., Appellee ______________________ 2021-1777 ______________________ Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR201901340. ______________________ Decided: March 18, 2022 ______________________ PRATIK A. SHAH, Akin Gump Strauss Hauer & Feld LLP, Washington, DC, argued for appellant. Also represented by Z.W. JULIUS CHEN; MICHAEL P. KAHN, New York, NY; DAVID A. CAINE, Arnold & Porter Kaye Scholer LLP, Palo Alto, CA; MATTHEW WOLF, Washington, DC. RICHARD CRUDO, Sterne Kessler Goldstein & Fox, Washington, DC, argued for appellee. Also represented by Case: 21-1777 Document: 40 2 Page: 2 Filed: 03/18/2022 BOSTON SCIENTIFIC v. NEVRO CORP. NAVEED HASAN, JON WRIGHT; CHING-LEE FUKUDA, Sidley Austin LLP, New York, NY. ______________________ Before MOORE, Chief Judge, CHEN and HUGHES, Circuit Judges. HUGHES, Circuit Judge. Boston Scientific Neuromodulation Corp. appeals a decision of the Patent Trial and Appeal Board invalidating all claims of U.S. Patent No. 6,381,496 as obvious. Because substantial evidence supports the Board’s factual findings, we affirm. I U.S. Patent No. 6,381,496 relates to implant devices that allow users to modify therapy parameters. For example, a spinal cord stimulation device uses parameters like amplitude, width, and frequency to create electric pulses that the device sends to a patient’s spinal cord. The ’496 patent discloses a device that can switch from one set of values for these operational parameters to another. Claim 1 is representative: 1. An implant device comprising: an implantable case; electronic circuitry housed within said implantable case for performing a prescribed function, the electronic circuitry including a control register wherein a control set of operational parameters is stored, a controller that controls the operation of the implant device as a function of the control set of operational parameters stored in the control register, and a plurality of sets of operational parameters; and Case: 21-1777 Document: 40 BOSTON SCIENTIFIC Page: 3 Filed: 03/18/2022 v. NEVRO CORP. 3 selection means for selecting one of the plurality of sets of operational parameters as the control set of operational parameters that is stored in the control register; whereby the operation of the implant device may be changed through selection of a different set of operational parameters. ’496 patent at 19:47–64. Nevro Corp. petitioned for inter partes review of all claims of the ’496 patent, asserting seven obviousness grounds. The Board instituted review, agreed with all asserted grounds, and concluded that the ’496 patent is unpatentable as obvious. Boston Scientific appeals. We have jurisdiction under 28 U.S.C. § 1295(a)(4)(A). II We review the ultimate conclusion of obviousness de novo and subsidiary fact findings for substantial evidence. In re Ethicon, Inc., 844 F.3d 1344, 1349 (Fed. Cir. 2017). Boston Scientific argues that the Board misconstrued the term “set of operational parameters” by allowing a set to contain only one parameter even though the patent uses the plural term “parameters.” Boston Scientific asserts that this error is material because the prior art reference Shelton (U.S. Patent No. 5,387,228) teaches modifying only a single parameter. Boston Scientific further argues that Shelton does not teach the ’496 patent’s “selecting one of the plurality of sets of operational parameters as the control set” limitation. While Nevro disagrees with Boston Scientific’s arguments about Shelton, it tells us we should instead focus on the prior art reference Nappholz (U.S. Patent No. 5,720,770). According to Nevro, Nappholz discloses modifying multiple parameters—rendering any claim Case: 21-1777 4 Document: 40 Page: 4 Filed: 03/18/2022 BOSTON SCIENTIFIC v. NEVRO CORP. construction error harmless—and teaches the disputed limitation. We agree with Nevro. Substantial evidence supports the Board’s factual finding that Nappholz teaches “selecting one of the plurality of sets of operational parameters as the control set.” Nappholz’s claims 10 and 27 teach a system that switches between “first and second therapies” in response to a change in conditions. Nappholz at 16:1–12, 17:13–22. And Nappholz’s figure 7 depicts a flowchart in which the device detects a change in the user’s activity level, asks the user what activity she is performing (e.g., sleeping, waking up, exercising), and then adjusts the operational parameters accordingly. See id. at 9:19–29. These disclosures constitute substantial evidence supporting the Board’s finding that Nappholz teaches “a plurality of sets of operational parameters” and means for selecting one set as the control set. We also do not need to determine whether a “set of operational parameters” must contain more than one parameter because Nappholz teaches sets containing more than one parameter. See id. at 15:14–25 (claiming means for exchanging information with an implantable cardiac device, “said information including . . . commands for modifying [a plurality of] programmable parameters”). We affirm the Board’s decision. AFFIRMED
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
